person · Reporting owner
Apeiron Investment Group Ltd.
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atai Beckley N.V.ATAI · Entity 72536 | 10% owner | September 30, 2025 | October 02, 2025 |
| Enhanced Group Inc.ENHA · Entity 6262 | Director · 10% owner | September 17, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atai Beckley N.V.
Report date September 30, 2025 · Filed October 02, 2025
Jointly reported with Angermayer Christian
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Apeiron Investment Group Ltd. | 53,412,414 |
Reported balance
After 2025-09-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-09-30 · Conversion · Acquired 2,367,200 · Balance 53,412,414 F1: The conversion price for the Convertible Notes is EUR 17.00 per note. |
| Convertible NotesSEC Table II · derivative / convertible security · Expires 2025-09-30 | IndirectBy Apeiron Investment Group Ltd. | 0 |
Reported balance
After 2025-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-30 · Conversion · Disposed 147,950 · Balance 0 F1: The conversion price for the Convertible Notes is EUR 17.00 per note. F2: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics. |
| Common SharesSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P. | 1,799,302 |
Reported balance
Holding disclosure · report date 2025-09-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,799,302 |
Filing footnotes · ownership attribution and instrument terms
F1: The conversion price for the Convertible Notes is EUR 17.00 per note.
F2: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.
Enhanced Group Inc.
Report date September 17, 2026 · Filed September 22, 2026
Jointly reported with Enhanced Holdings LP, Angermayer Christian
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 43,343,818 |
Reported balance
After 2026-09-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-09-17 · Purchase · Acquired 6,080,047 · Balance 43,343,818 F1: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Alto Neuroscience, Inc.
Report date February 06, 2024 · Filed March 06, 2024
Jointly reported with Apeiron Presight Capital Fund II, L.P., Angermayer Christian
Section 16 reporting ended · disclosed 2024-03-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,881 |
Reported balance
After 2024-02-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-06 · Conversion · Acquired 251,881 · Balance 251,881 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
| Common StockSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P.( | 674,658 |
Reported balance
After 2024-02-06 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-02-06 · Conversion · Acquired 674,658 · Balance 674,658 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Warrants to Purchase Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-06 · Conversion · Disposed 444,561 · Balance 0 F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-06 · Conversion · Disposed 406,072 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Apeiron Presight Capital Fund II, L.P. | 0 |
Reported balance
After 2024-02-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-06 · Conversion · Disposed 1,063,918 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Apeiron Presight Capital Fund II, L.P. | 0 |
Reported balance
After 2024-02-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-06 · Conversion · Disposed 416,665 · Balance 0 F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.
F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.
F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.
AtaiBeckley Inc.
Report date September 11, 2026 · Filed September 11, 2026
Jointly reported with Angermayer Christian
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-09-11 · Disposition to issuer · Disposed 559,232 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. |
| Common StockSEC Table I · non-derivative | IndirectBy ApeironInvestmentGroup Ltd. | 0 |
Reported balance
After 2026-09-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-09-11 · Disposition to issuer · Disposed 53,398,214 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. F3: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy ApeironPresightCapital FundII, L.P. | 0 |
Reported balance
After 2026-09-11 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-09-11 · Disposition to issuer · Disposed 1,799,302 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.68 · Expires 2030-08-20 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-11 · Disposition to issuer · Disposed 624,000 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2033-05-23 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-11 · Disposition to issuer · Disposed 17,930 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2034-01-05 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-11 · Disposition to issuer · Disposed 1,247,932 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2035-06-02 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-11 · Disposition to issuer · Disposed 131,698 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-11 · Disposition to issuer · Disposed 121,968 · Balance 0 F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
F3: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4.
F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
BIONOMICS LTD/ADR
Report date July 01, 2024 · Filed October 07, 2024
Jointly reported with Apeiron Presight Capital Fund II, L.P., Angermayer Christian
Section 16 reporting ended · disclosed 2024-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P. | 125,996,580 |
Reported balance
After 2024-10-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-10-02 · Sale · Disposed 90,806 · Balance 125,996,580 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P. | 93,469,320 |
Reported balance
After 2024-10-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-10-03 · Sale · Disposed 180,707 · Balance 93,469,320 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Presight Capital Fund II, L.P. | 93,369,060 |
Reported balance
After 2024-10-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-10-04 · Sale · Disposed 557 · Balance 93,369,060 F1: Includes Ordinary Shares represented by American Depositary Shares. F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Apeiron Investment Group Ltd. | 183,121,441 |
Reported balance
Holding disclosure · report date 2024-07-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 183,121,441 F1: Includes Ordinary Shares represented by American Depositary Shares. F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes Ordinary Shares represented by American Depositary Shares.
F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
Faeth Therapeutics, Inc.
Report date June 01, 2023 · Filed June 02, 2023
Jointly reported with Angermayer Christian, Presight Sensei Co-Invest Fund, L.P., Presight Co-Invest Management, L.L.C.
Section 16 reporting ended · disclosed 2023-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Apeiron Investment Group Ltd. | 0 |
Reported balance
After 2023-06-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-01 · Sale · Disposed 2,485,923 · Balance 0 F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron. |
| Common StockSEC Table I · non-derivative | IndirectBy Presight Sensei Co-Invest Fund, L.P. | 0 |
Reported balance
After 2023-06-01 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-06-01 · Sale · Disposed 955,738 · Balance 0 F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F2: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.
F3: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 22, 2026 01:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 6,080,047 | $1.15 | $6,992,054.05 |
DisclosureSEC source: 0001193125-26-397056 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 43,343,818 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 121,968 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · derivative · entry 10 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,968 shares Expires 2036-06-04 F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 103,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · derivative · entry 9 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2035-06-26 F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 131,698 | Not disclosed Strike: $2.49 | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · derivative · entry 8 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,698 shares Expires 2035-06-02 F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 1,247,932 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · derivative · entry 7 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,247,932 shares Expires 2034-01-05 F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 17,930 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · derivative · entry 6 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,930 shares Expires 2033-05-23 F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 64,000 | Not disclosed Strike: $3.84 | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · derivative · entry 5 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2032-05-25 F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 624,000 | Not disclosed Strike: $5.68 | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · derivative · entry 4 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 624,000 shares Expires 2030-08-20 F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerCommon Stock | 1,799,302 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · nonDerivative · entry 3 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ApeironPresightCapital FundII, L.P. Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerCommon Stock | 53,398,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · nonDerivative · entry 2 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ApeironInvestmentGroup Ltd. Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. F3 · balance_after: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerCommon Stock | 559,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036377 · form4.xml · nonDerivative · entry 1 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 23:08 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 99,342 | $1.60 | $159,374.37 |
DisclosureSEC source: 0001193125-26-386771 · ownership.xml · nonDerivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 37,263,771 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 23:08 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 59,337 | $1.57 | $93,076.02 |
DisclosureSEC source: 0001193125-26-386771 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 37,164,429 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 23:08 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 21,034 | $1.61 | $33,898.39 |
DisclosureSEC source: 0001193125-26-386771 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 37,105,092 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 25,414 | $1.58 | $40,151.58 |
DisclosureSEC source: 0001193125-26-383717 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 37,084,058 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 107,693 | $1.58 | $169,627.24 |
DisclosureSEC source: 0001193125-26-383717 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 37,058,644 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 11:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 55,000 | $1.64 | $90,381.50 |
DisclosureSEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 4 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 36,950,951 F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 11:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 1,619,316 | $1.66 | $2,688,064.56 |
DisclosureSEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 36,895,951 F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 11:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 93,000 | $1.70 | $158,211.60 |
DisclosureSEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 35,276,635 F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 12:55 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 200,000 | $1.65 | $330,420.00 |
DisclosureSEC source: 0001193125-26-354788 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 33,062,812 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 10:10 UTC | Enhanced Group Inc. ENHA · Entity 6262 | PurchaseClass A Common Stock | 150,000 | $1.97 | $295,620.00 |
DisclosureSEC source: 0001193125-26-353161 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 32,862,812 F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2026 Filed Aug 20, 2026 11:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | GrantWarrants · Derivative | 2,120,823 | Not disclosed Strike: $3.89 | Not disclosed |
DisclosureSEC source: 0001193125-26-357979 · ownership.xml · derivative · entry 5 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 5,141,388 Underlying: Class A Common Stock · 2,120,823 shares Expires not disclosed F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On August 14, 2026, the second tranche of the Private Placement closed. F4 · derivative.exercise_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days. F4 · derivative.expiration_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days. F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2026 Filed Aug 20, 2026 11:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | GrantClass A Common Stock | 2,120,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 35,183,635 F1 · kind: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On August 14, 2026, the second tranche of the Private Placement closed. F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On August 14, 2026, the second tranche of the Private Placement closed. F2 · balance_after: The total in Column 5 of Table I represents the amount of Class A Common Stock held by the Reporting Persons as of the date of this filing. F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 22, 2026 Filed Jul 24, 2026 22:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | GrantWarrants · Derivative | 3,020,565 | Not disclosed Strike: $3.89 | Not disclosed |
DisclosureSEC source: 0001193125-26-316451 · ownership.xml · derivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,020,565 Underlying: Class A Common Stock · 3,020,565 shares Expires not disclosed F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On July 22, 2026, the first tranche of the Private Placement closed. F3 · derivative.exercise_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days. F3 · derivative.expiration_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days. F2 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 22, 2026 Filed Jul 24, 2026 22:30 UTC | Enhanced Group Inc. ENHA · Entity 6262 | GrantClass A Common Stock | 3,020,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-316451 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 32,712,812 F1 · kind: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On July 22, 2026, the first tranche of the Private Placement closed. F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On July 22, 2026, the first tranche of the Private Placement closed. F2 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 07, 2026 Filed May 11, 2026 22:51 UTC | Enhanced Group Inc. ENHA · Entity 6262 | GrantWarrants · Derivative | 212,499 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001193125-26-217397 · ownership.xml · derivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 212,499 Underlying: Class A Common Stock · 212,499 shares Expires not disclosed F1 · price: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd. F3 · derivative.exercise_date: The warrants are currently exercisable and have a two-year term, which may be accelerated if the Class A Common Stock trades at or above $15 for at least twenty of thirty consecutive trading days. F3 · derivative.expiration_date: The warrants are currently exercisable and have a two-year term, which may be accelerated if the Class A Common Stock trades at or above $15 for at least twenty of thirty consecutive trading days. F2 · ownership.nature: The securities are held directly by Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities held directly by Enhanced Holdings LP. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 07, 2026 Filed May 11, 2026 22:51 UTC | Enhanced Group Inc. ENHA · Entity 6262 | GrantClass B Common Stock | 258,837,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-217397 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 258,837,933 F1 · kind: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd. F1 · price: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd. F2 · ownership.nature: The securities are held directly by Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities held directly by Enhanced Holdings LP. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 07, 2026 Filed May 11, 2026 22:51 UTC | Enhanced Group Inc. ENHA · Entity 6262 | GrantClass A Common Stock | 29,692,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-217397 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 29,692,247 F1 · kind: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd. F1 · price: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd. F2 · ownership.nature: The securities are held directly by Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities held directly by Enhanced Holdings LP. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 103,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001140361-26-014300 · form4.xml · derivative · entry 8 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2034-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 410,162 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001140361-26-014300 · form4.xml · derivative · entry 7 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,838 Underlying: Common Stock · 410,162 shares Expires 2034-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the shares on January 5, 2025, and will vest with respect to the remaining shares in 36 monthly installments thereafter. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 46,070 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001140361-26-014300 · form4.xml · derivative · entry 6 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,930 Underlying: Common Stock · 46,070 shares Expires 2033-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 103,000 | $1.34 | $138,020.00 |
DisclosureSEC source: 0001140361-26-014300 · form4.xml · nonDerivative · entry 3 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired upon exercise of options and held by the Reporting Person. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 410,162 | $1.64 | $672,665.68 |
DisclosureSEC source: 0001140361-26-014300 · form4.xml · nonDerivative · entry 2 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired upon exercise of options and held by the Reporting Person. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 46,070 | $1.88 | $86,611.60 |
DisclosureSEC source: 0001140361-26-014300 · form4.xml · nonDerivative · entry 1 Angermayer Christian · CIK 0001845872 · Director · 10% owner Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired upon exercise of options and held by the Reporting Person. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 16:18 UTC | Atai Beckley N.V. ATAI · Entity 72536 | ConversionConvertible Notes · Derivative | 147,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-228361 · ownership.xml · derivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 0 Underlying: Common Shares · 2,367,200 shares Expires 2025-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The conversion price for the Convertible Notes is EUR 17.00 per note. F2 · price: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 16:18 UTC | Atai Beckley N.V. ATAI · Entity 72536 | ConversionCommon Shares | 2,367,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-228361 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 53,412,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The conversion price for the Convertible Notes is EUR 17.00 per note. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 18:00 UTC | Atai Beckley N.V. ATAI · Entity 72536 | PurchaseCommon Shares | 8,675,799 | $2.19 | $18,999,999.81 |
DisclosureSEC source: 0000950170-25-109858 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 51,045,214 Read SEC document |
| March 24, 2025 Filed Mar 24, 2025 17:00 UTC | Atai Beckley N.V. ATAI · Entity 72536 | PurchaseCommon Shares | 1,800,000 | $1.40 | $2,520,000.00 |
DisclosureSEC source: 0000950170-25-043942 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 42,369,415 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 18:00 UTC | Atai Beckley N.V. ATAI · Entity 72536 | PurchaseCommon Shares | 10,835,718 | $2.10 | $22,755,007.80 |
DisclosureSEC source: 0000950170-25-023436 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 40,555,215 Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 18:22 UTC | BIONOMICS LTD/ADR BNOX · Entity 86952 | SaleOrdinary Shares | 557 | $0.28 | $155.96 |
DisclosureSEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 93,369,060 F1 · security: Includes Ordinary Shares represented by American Depositary Shares. F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 18:22 UTC | BIONOMICS LTD/ADR BNOX · Entity 86952 | SaleOrdinary Shares | 180,707 | $0.29 | $52,405.03 |
DisclosureSEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 93,469,320 F1 · security: Includes Ordinary Shares represented by American Depositary Shares. F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| October 02, 2024 Filed Oct 7, 2024 18:22 UTC | BIONOMICS LTD/ADR BNOX · Entity 86952 | SaleOrdinary Shares | 90,806 | $0.33 | $29,965.98 |
DisclosureSEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 125,996,580 F1 · security: Includes Ordinary Shares represented by American Depositary Shares. F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 16:15 UTC | Atai Beckley N.V. ATAI · Entity 72536 | OtherConvertible Notes · Derivative | 147,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-045120 · ownership.xml · derivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 147,950 Underlying: Common Shares · 2,367,200 shares Expires 2025-09-30 F1 · derivative.exercise_price: The conversion price for the Convertible Notes is EUR 17.00 per note. F2 · kind: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics. F3 · shares: Each Convertible Note bears a notional principal amount of EUR 1.00. F2 · price: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics. F3 · balance_after: Each Convertible Note bears a notional principal amount of EUR 1.00. F4 · ownership.nature: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 16:15 UTC | Atai Beckley N.V. ATAI · Entity 72536 | OtherConvertible Notes · Derivative | 147,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-045120 · ownership.xml · derivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner Angermayer Christian · CIK 0001845872 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Investment Group Ltd. Disclosed balance after: 0 Underlying: Common Shares · 2,367,200 shares Expires not disclosed F1 · derivative.exercise_price: The conversion price for the Convertible Notes is EUR 17.00 per note. F2 · kind: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics. F3 · shares: Each Convertible Note bears a notional principal amount of EUR 1.00. F2 · price: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics. F2 · derivative.exercise_date: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics. F2 · derivative.expiration_date: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics. F4 · ownership.nature: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries B Preferred Stock · Derivative | 416,665 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 6 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 196,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F5 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F5 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries A Preferred Stock · Derivative | 1,063,918 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 5 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 478,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries A Preferred Stock · Derivative | 406,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 4 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 182,577 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionWarrants to Purchase Series A Preferred Stock · Derivative | 444,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 3 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,304 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F4 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 674,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 2 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.( Disclosed balance after: 674,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities. Read SEC document |
| February 06, 2024 Filed Mar 6, 2024 14:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 251,881 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 1 Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks Angermayer Christian · CIK 0001845872 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis. F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.